Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/27/2025

Treatment Options for Urinary Frequency in Men

Initial Evaluation

  • The American Urological Association recommends obtaining a thorough medical history, conducting a physical examination including digital rectal examination (DRE), utilizing the International Prostate Symptom Score (IPSS), and performing urinalysis for all men presenting with urinary frequency 1, 2
  • A frequency-volume chart (FVC) should be completed for 3 days, especially when nocturia is a significant component of the symptoms 3, 4
  • The degree of bother and impact on quality of life should be assessed, as this should guide treatment decisions 1, 2
  • Measuring post-void residual (PVR) volume can help evaluate for urinary retention 1, 5

Understanding the Causes

  • Benign prostatic hyperplasia (BPH) causing benign prostatic obstruction (BPO) is the most common cause of urinary frequency in men over 50 1
  • Overactive bladder (OAB) syndrome can occur independently or secondary to BPH 1, 6
  • Nocturnal polyuria, or excessive urine production at night, can also contribute to urinary frequency 7, 3
  • Urinary tract infections can cause urinary frequency 5

Treatment Algorithm

  • Alpha-blockers, such as tamsulosin or alfuzosin, are recommended as first-line therapy for most men with lower urinary tract symptoms (LUTS) 1
  • For men with a prostate size greater than 30cc, adding 5-alpha reductase inhibitors (5ARIs) such as finasteride or dutasteride may be considered 1
  • Phosphodiesterase-5 inhibitors, such as tadalafil, can be used as an alternative option, especially for men with concurrent erectile dysfunction 1
  • Anticholinergics, such as trospium or oxybutynin, can be used to treat overactive bladder (OAB) symptoms 1, 6

Special Considerations

  • Men with predominant nocturia should be evaluated for nocturnal polyuria (>33% of 24-hour urine output occurring at night) 7, 6
  • Combination therapy should be considered when monotherapy fails 1

Treatment Monitoring

  • Follow-up should occur 4-12 weeks after initiating treatment to assess response 1
  • Annual follow-up is recommended for stable patients to monitor for symptom progression 6
  • Repeating IPSS and PVR measurement at follow-up visits can help monitor treatment effectiveness 1